Ridgeline FIT sells research peptides exclusively to qualified researchers and laboratories for in vitro and laboratory use. Please confirm before continuing.
By proceeding you affirm the statements above are true. Products are not for human or veterinary use, not for use in diagnostic procedures, and have not been evaluated by the U.S. Food and Drug Administration. Full disclaimer.
$59.99
Melanotan II is a synthetic cyclic peptide analogue of the natural hormone Alpha-melanocyte stimulating hormone (α-MSH). It was developed in the 1980s and acts as a non-selective agonist of multiple melanocortin receptors (including MC₁R, MC₃R, MC₄R and MC₅R) in order to examined in laboratory models for melanocortin receptor signaling and pathway analysis.
Sequence (simplified): Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ (a cyclic heptapeptide)
Molecular formula: C₅₀H₆₉N₁₅O₉
Approximate molecular weight: ~1,024.2 g/mol
Mechanistic note: The cyclic structure and non-natural amino acid residues enhance receptor affinity and metabolic stability compared to the native hormone.
Observed Research Findings in Laboratory Models
Pigmentation / Melanogenesis: studied for associations with MC₁R signaling and melanogenesis pathways in vitro.
Appetite & Energy Regulation: examined in experimental systems for modulation of MC₃R/MC₄R signaling and metabolic pathways.
Sexual & Reproductive Effects: studied in preclinical and translational models for associations with MC₄R signaling in neuroendocrine pathways.
Research & Safety Considerations: research notes potential associations with pigmentation and systemic signaling changes in experimental contexts.
This product is intended strictly for laboratory or research use only. It is not approved for human, veterinary, or dietary administration. Always handle under proper laboratory conditions, with qualified personnel. Keep away from unauthorized use. The information provided here is for educational/research context and does not constitute medical or therapeutic advice.
Reviews
There are no reviews yet.